Stem Cells for Crohn's Disease: A Breakthrough in IBD Treatment
From the first EU-approved stem cell therapy (Darvadstrocel) for Crohn's fistulas to immune system reset via HSCT, stem cells are reshaping how we treat inflammatory bowel disease.
Understanding Crohn's Disease
Crohn's disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to anus, though it most commonly involves the terminal ileum and colon. It causes transmural inflammation (affecting the full thickness of the bowel wall), leading to symptoms including abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Over time, it can cause serious complications including strictures (narrowing), fistulas (abnormal connections between organs), and abscesses.
Crohn's disease affects approximately 3 million people in Europe and North America, with incidence rising globally. Despite advances in biological therapies (anti-TNF agents, vedolizumab, ustekinumab), approximately 20-30% of patients fail to respond to available treatments, and many who initially respond lose efficacy over time. Up to 70% of patients eventually require surgery, and disease recurrence after surgery is common.
Perianal fistulas — one of the most debilitating complications — affect up to 26% of Crohn's patients. These abnormal tunnels between the bowel and the skin around the anus cause chronic pain, discharge, and significantly impair quality of life. They are notoriously difficult to treat, with conventional therapies achieving sustained healing in fewer than 40% of cases. It is for this specific complication that stem cell therapy has already achieved regulatory approval.
MSC Therapy for Perianal Fistulas
The approval of Darvadstrocel (Alofisel) in 2018 by the European Medicines Agency marked a historic milestone — one of the first stem cell therapies approved for any disease worldwide. This treatment uses expanded allogeneic adipose-derived MSCs injected directly into Crohn's perianal fistula tracts.
Anti-Inflammatory Action
MSCs injected into the fistula tract reduce the intense local inflammation that prevents healing. They suppress pro-inflammatory cytokines (TNF-α, IL-17, IFN-γ) and promote anti-inflammatory mediators (IL-10, TGF-β), creating an environment conducive to tissue repair.
Tissue Regeneration
MSC-secreted growth factors stimulate local fibroblasts to produce new collagen and extracellular matrix, physically closing the fistula tract. Unlike surgical approaches that leave scar tissue, MSC-mediated closure promotes more natural tissue architecture.
Immune Modulation
MSCs modulate the overactive immune response locally, preventing the continued immune-mediated tissue destruction that keeps fistulas open. They suppress pathogenic T helper 17 (Th17) cells while promoting regulatory T cells (Tregs) that maintain immune tolerance.
Clinical Results
The Phase III ADMIRE-CD trial showed 51.5% combined fistula remission at 24 weeks (vs. 35.6% placebo). Long-term follow-up demonstrated sustained healing in responders. The treatment has a favorable safety profile with adverse events similar to placebo.
HSCT: Resetting the Immune System
For patients with severe, treatment-refractory Crohn's disease, autologous hematopoietic stem cell transplantation (HSCT) offers a more radical approach: completely resetting the immune system. The procedure involves collecting the patient's own blood-forming stem cells, then using high-dose chemotherapy to destroy the dysfunctional immune system, followed by reinfusion of the stored stem cells to rebuild a new immune system from scratch.
The ASTIC trial and subsequent studies showed that approximately 70% of patients with severe, refractory Crohn's disease achieved clinical remission after HSCT, with many maintaining drug-free remission for years. Some patients showed complete endoscopic healing — the gold standard for Crohn's treatment — something rarely achieved with any other therapy.
However, HSCT is not without significant risks. The conditioning chemotherapy carries risks of infection, organ toxicity, and treatment-related mortality (historically 1-5%, though modern protocols have improved safety). HSCT for Crohn's is reserved for carefully selected patients who have failed all available biological therapies and face significant morbidity from uncontrolled disease.
HSCT for Crohn's disease is a high-risk procedure reserved for patients with severe, treatment-refractory disease. It should only be considered after exhausting all conventional and biological therapies, and should be performed at specialized transplant centers with IBD expertise. Discuss all risks and benefits thoroughly with your gastroenterologist and transplant team.
Systemic MSC Therapy for Intestinal Inflammation
Beyond fistula treatment, MSC therapy is being investigated for systemic Crohn's disease — addressing the intestinal inflammation that drives the condition. When administered intravenously, MSCs home to inflamed gut tissue and exert their immunomodulatory effects throughout the gastrointestinal tract.
Reduced Disease Activity
Clinical trials of IV MSC infusion in Crohn's patients have shown significant reductions in CDAI (Crohn's Disease Activity Index) scores, with some patients achieving clinical remission. Inflammatory biomarkers (CRP, fecal calprotectin) also decreased significantly.
Mucosal Healing
Endoscopic evaluation after MSC therapy has shown improvement in mucosal inflammation and early evidence of healing in some patients, suggesting MSCs can address the structural damage caused by Crohn's inflammation.
Steroid-Sparing Effect
Some patients treated with MSC therapy were able to reduce or eliminate corticosteroid use while maintaining disease control, reducing the significant side effects associated with long-term steroid use in Crohn's disease.
Combination Potential
MSC therapy may be most effective when combined with existing biological therapies, potentially enhancing their efficacy or restoring response in patients who have developed anti-drug antibodies. This combination approach is being actively investigated in clinical trials.
Frequently Asked Questions
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Crohn's disease management should be guided by a qualified gastroenterologist. Do not discontinue prescribed medications. StemCell Longevita operates as an international patient coordination platform.
Coordinamento Internazionale dei Pazienti
StemCell Longevita opera come piattaforma di coordinamento internazionale dei pazienti. Mettiamo in contatto i pazienti con istituzioni mediche autorizzate che offrono applicazioni di medicina rigenerativa dopo valutazione medica e nel rispetto dei quadri normativi applicabili. Tutte le decisioni e le procedure mediche sono condotte esclusivamente da professionisti sanitari autorizzati. StemCell Longevita non fornisce direttamente trattamenti medici.
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as medical advice. Stem cell therapy is an evolving field, and outcomes may vary by individual. The treatments described on this site have not been fully evaluated or approved by the FDA or equivalent regulatory bodies in all jurisdictions.
The FDA has not approved stem cell applications for most conditions listed on this website. Results mentioned are based on clinical observations, published research, and patient-reported outcomes. Individual results may vary and no specific outcomes are assured for any individual patient.
L'inclusione di pubblicazioni scientifiche su questo sito non implica approvazione normativa o risultati clinici garantiti. Alcune applicazioni possono essere considerate sperimentali a seconda dell'indicazione e della giurisdizione.
Always consult with a qualified healthcare professional before making any medical decisions. Do not disregard professional medical advice or delay seeking treatment based on information found on this website.